rofecoxib and Cardiovascular Stroke studies

Research Excerpts

Excerpt	Relevance	Reference
"To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia."	9.05	Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020)
"We tested the time to signal detection of quantitative ADR signalling methods in a health claims database (SSA) and in a spontaneous reporting database (ROR, PRR, Bayesian confidence propagation neural network) for rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure."	7.80	Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. ( A Wahab, I; Kalisch, LM; Pratt, NL; Roughead, EE, 2014)
"Rofecoxib has been proposed to increase the risk of myocardial infarction (MI) through suppression of cyclooxygenase 2–mediated prostacyclin."	7.77	Exogenous estrogen does not attenuate the association between rofecoxib and myocardial infarction in perimenopausal women. ( Brensinger, CM; Ellenberg, JH; Grosser, T; Hennessy, S; Kimmel, SE; Wade, KC, 2011)
"A retrospective cohort study in 38 258 veteran patients (26 376 patient-years) measured the adjusted odds ratios of acute myocardial infarction during exposure to etodolac, naproxen, celecoxib, or rofecoxib."	7.74	The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. ( Banerjee, S; Brilakis, ES; Cryer, B; Cunningham, F; Harford, WV; Kazi, S; Kelly, KC; Little, BB; Warner, JJ; Weideman, RA, 2008)
"The VIOXX Gastrointestinal Outcomes Research (VIGOR) trial showed a 53% decrease in the risk of upper gastrointestinal toxicity and a fivefold increase in the risk of myocardial infarction for rofecoxib (a selective cyclooxygenase-2 inhibitor) compared with naproxen."	7.72	Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2004)
"Rofecoxib increased overall the arrhythmias including ventricular fibrillation (VF) during I/R."	5.56	Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion. ( Baczkó, I; Baranyai, T; Brenner, GB; Ferdinandy, P; Gergely, TG; Giricz, Z; Görbe, A; Husti, Z; Kiss, B; Lázár, B; Makkos, A; Nagy, CT; Onódi, Z; Sághy, É; Sayour, NV; Schulz, R; Tóthfalusi, L; Varga, RS; Varró, A; Zádori, ZS, 2020)
"Celecoxib and rofecoxib were associated with different odds of MI."	5.33	Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2005)
"To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia."	5.05	Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020)
"Rofecoxib, but perhaps not all cyclooxygenase-2 inhibitors, may be associated with increased risk for myocardial infarction."	4.82	Cyclooxygenase-2 inhibitors. ( Fortun, PJ; Hawkey, CJ, 2005)
"We tested the time to signal detection of quantitative ADR signalling methods in a health claims database (SSA) and in a spontaneous reporting database (ROR, PRR, Bayesian confidence propagation neural network) for rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure."	3.80	Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. ( A Wahab, I; Kalisch, LM; Pratt, NL; Roughead, EE, 2014)
"Rofecoxib has been proposed to increase the risk of myocardial infarction (MI) through suppression of cyclooxygenase 2–mediated prostacyclin."	3.77	Exogenous estrogen does not attenuate the association between rofecoxib and myocardial infarction in perimenopausal women. ( Brensinger, CM; Ellenberg, JH; Grosser, T; Hennessy, S; Kimmel, SE; Wade, KC, 2011)
"To investigate trends in mortality rates due to both myocardial infarction and gastrointestinal haemorrhage before and after rofecoxib withdrawal and the release of regulatory guidance regarding the use of other COX-2 inhibitors."	3.76	International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction. ( Gunnell, D; Martin, RM; Metcalfe, C; Wheeler, BW, 2010)
" cerebral infarction, myocardial infarction and unstable angina pectoris, among rofecoxib and naproxen users in comparison to diclofenac users."	3.76	Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study. ( Einarsdottir, R; Gudbjornsson, B; Halldorsson, M; Johannsson, M; Sigvaldason, H; Thorgeirsson, G; Thorsteinsson, SB; Zoega, H, 2010)
"The objective of this study was to determine whether a selective cyclooxygenase-2 inhibitor (rofecoxib) could alter the evolution of acute myocardial infarction after reperfusion."	3.75	Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia. ( Carnieto, A; Chagas, AC; Dourado, PM; Luz, PL, 2009)
" Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0."	3.75	Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009)
" Ischemic stroke was predicted by hypertension, myocardial infarction, low-dose aspirin, comorbidity score, Health Assessment Questionnaire score, and presence of total joint replacement, but not by diabetes, smoking, exercise, or body mass index."	3.74	Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. ( Hallenbeck, JM; Michaud, K; Nadareishvili, Z; Wolfe, F, 2008)
"A retrospective cohort study in 38 258 veteran patients (26 376 patient-years) measured the adjusted odds ratios of acute myocardial infarction during exposure to etodolac, naproxen, celecoxib, or rofecoxib."	3.74	The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. ( Banerjee, S; Brilakis, ES; Cryer, B; Cunningham, F; Harford, WV; Kazi, S; Kelly, KC; Little, BB; Warner, JJ; Weideman, RA, 2008)
"Although only rofecoxib use was associated with an increased risk of myocardial infarction in those without a previous event, both rofecoxib and celecoxib were associated with an excess risk of acute myocardial infarction for current users with a history of myocardial infarction."	3.74	The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. ( Brophy, JM; Lévesque, LE; Zhang, B, 2007)
"To evaluate the association between rofecoxib, celecoxib, diclofenac, and ibuprofen and the risk of hospitalization for acute myocardial infarction (AMI) in an elderly population."	3.74	Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. ( Kong, SX; LeLorier, J; Rahme, E; Toubouti, Y; Watson, DJ, 2007)
"Using national data (2001-2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam."	3.73	Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. ( Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW, 2006)
" Using data collected in a previous population-based cohort study of elderly people starting nonsteroidal anti-inflammatory drug (NSAID) therapy, we evaluated the temporal nature of the risk of a first myocardial infarction (MI) associated with the use of rofecoxib and celecoxib."	3.73	Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. ( Brophy, JM; Lévesque, LE; Zhang, B, 2006)
"To simultaneously assess the short-term reduction in risk of gastrointestinal (GI) complications and increase in risk of acute myocardial infarction (MI) by celecoxib compared with rofecoxib and several nonselective nonsteroidal antiinflammatory drugs (NSAIDs) using instrumental variable analysis."	3.73	Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. ( Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS, 2006)
"The VIOXX Gastrointestinal Outcomes Research (VIGOR) trial showed a 53% decrease in the risk of upper gastrointestinal toxicity and a fivefold increase in the risk of myocardial infarction for rofecoxib (a selective cyclooxygenase-2 inhibitor) compared with naproxen."	3.72	Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2004)
" We studied the relative risk of acute myocardial infarction (AMI) among users of celecoxib, rofecoxib, and NSAIDs in Medicare beneficiaries with a comprehensive drug benefit."	3.72	Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. ( Avorn, J; Glynn, RJ; Kiyota, Y; Levin, R; Mogun, H; Schneeweiss, S; Solomon, DH, 2004)
" Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction."	3.72	[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004)
" As of December 2000, 21 of these trials had been completed (70%), and the risk of a CVT adverse event or death was greater among subjects assigned to the rofecoxib group (rate ratio [RR], 2."	2.45	Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. ( Egilman, DS; Hill, KP; Krumholz, HM; Madigan, D; Ross, JS; Wang, Y, 2009)
" An increased risk was observed for diclofenac and rofecoxib, the latter one with a clear dose-response trend."	2.43	Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. ( García Rodríguez, LA; Hernández-Díaz, S; Varas-Lorenzo, C, 2006)
"Rofecoxib increased overall the arrhythmias including ventricular fibrillation (VF) during I/R."	1.56	Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion. ( Baczkó, I; Baranyai, T; Brenner, GB; Ferdinandy, P; Gergely, TG; Giricz, Z; Görbe, A; Husti, Z; Kiss, B; Lázár, B; Makkos, A; Nagy, CT; Onódi, Z; Sághy, É; Sayour, NV; Schulz, R; Tóthfalusi, L; Varga, RS; Varró, A; Zádori, ZS, 2020)
"We propose a practical group sequential method, a conditional sequential sampling procedure, to test if a drug of interest (D) leads to an elevated risk for an adverse event E compared with a comparison drug C."	1.35	A conditional sequential sampling procedure for drug safety surveillance. ( Li, L, 2009)
"Bayesian data mining methods have been used to evaluate drug safety signals from adverse event reporting systems and allow for evaluation of multiple endpoints that are not prespecified."	1.35	Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. ( Cheng, H; Curtis, JR; Delzell, E; Dumouchel, W; Fram, D; Kilgore, M; Saag, K; Yun, H, 2008)
"Rofecoxib treatment reduced global and systolic LV function after ischemia-reperfusion injury in APOE*3Leiden mice."	1.35	Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). ( Bekkers, ME; Corda, S; Emeis, JJ; Jukema, JW; Princen, HM; Steendijk, P; van der Hoorn, JW, 2008)
"Celecoxib and naproxen were not associated with increased risks."	1.35	Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. ( Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J, 2008)
"Celecoxib and rofecoxib were associated with different odds of MI."	1.33	Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2005)
"Naproxen was associated with an OR of 0."	1.32	Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. ( García Rodríguez, LA; González-Pérez, A; Maguire, A; Varas-Lorenzo, C, 2004)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	106 (89.08)	29.6817
2010's	9 (7.56)	24.3611
2020's	4 (3.36)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073]	Phase 2/Phase 3	84 participants (Actual)	Interventional	2017-04-04	Completed
Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645]	Phase 2	60 participants (Actual)	Interventional	2006-10-31	Completed
Single and Repeated Leech Therapy for the Treatment of Late Stage Knee Osteoarthritis. A Randomized, Placebo Controlled Comparative Trial[NCT00435773]	Phase 2	118 participants	Interventional	2004-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update. Drug safety, 2020, Volume: 43, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Cardiovascular Diseases; Cyclooxygenase 2 I	2020
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. The Cochrane database of systematic reviews, 2020, 04-30, Volume: 4 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age	2020
Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Archives of internal medicine, 2009, Nov-23, Volume: 169, Issue:21 Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular System; Cyclooxygenase 2 Inhibitors; Drug In	2009
Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drug safety, 2002, Volume: 25, Issue:12 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Suscept	2002
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications. Journal (Canadian Dental Association), 2005, Volume: 71, Issue:8 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials	2005
Cyclooxygenase-2 inhibitors. Current opinion in gastroenterology, 2005, Volume: 21, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Myo	2005
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic & clinical pharmacology & toxicology, 2006, Volume: 98, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cohort Studies; Diclofenac; Dose-Resp	2006
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Re	2007
Arthritis. Should you be taking a COX-2 inhibitor? Harvard health letter, 2001, Volume: 27, Issue:1 Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 1; Cycloo	2001
Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut, 2002, Volume: 50 Suppl 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In	2002

Article	Year
Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest, 2004, Volume: 125, Issue:5 Topics: Acute Disease; Angina, Unstable; C-Reactive Protein; Coronary Disease; Cyclooxygenase Inhibitors; Do	2004
Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes. International journal of cardiology, 2006, Oct-10, Volume: 112, Issue:3 Topics: Acute Disease; Adult; Aged; Angina, Unstable; C-Reactive Protein; Cyclooxygenase 2 Inhibitors; Doubl	2006
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatology international, 2007, Volume: 27, Issue:5 Topics: Adenoma; Adenomatous Polyps; Angina, Unstable; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactone	2007

Article	Year
Group sequential testing under instrumented difference-in-differences approach. Statistics in medicine, 2023, 09-20, Volume: 42, Issue:21 Topics: Bias; Humans; Myocardial Infarction; Safety-Based Drug Withdrawals; Statistics as Topic	2023
Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion. Cells, 2020, 02-26, Volume: 9, Issue:3 Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Cardiotoxicity; Cell Survival;	2020
Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PloS one, 2018, Volume: 13, Issue:11 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac;	2018
Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. Drug safety, 2014, Volume: 37, Issue:1 Topics: Adverse Drug Reaction Reporting Systems; Australia; Bayes Theorem; Cyclooxygenase 2 Inhibitors; Data	2014
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis and rheumatism, 2008, Aug-15, Volume: 59, Issue:8 Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An	2008
Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). Critical care medicine, 2008, Volume: 36, Issue:9 Topics: Animals; Apolipoprotein E3; Cyclooxygenase 2 Inhibitors; Hyperlipidemias; Immunohistochemistry; Lact	2008
Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. Medical care, 2008, Volume: 46, Issue:9 Topics: Adverse Drug Reaction Reporting Systems; Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal;	2008
Selective COX-2 inhibitors: new insights into mechanisms of side effects? Critical care medicine, 2008, Volume: 36, Issue:9 Topics: Animals; Cyclooxygenase 2 Inhibitors; Hemodynamics; Hyperlipidemias; Lactones; Mice; Myocardial Infa	2008
The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. Journal of cardiovascular pharmacology and therapeutics, 2008, Volume: 13, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitor	2008
Acute myocardial infarction after treatment of thrombocytopenia in a young woman with systemic lupus erythematosus. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008, Volume: 14, Issue:6 Topics: Antibodies, Antiphospholipid; Cyclooxygenase Inhibitors; Female; Humans; Immunoglobulins, Intravenou	2008
Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia. Clinics (Sao Paulo, Brazil), 2009, Volume: 64, Issue:3 Topics: Animals; Blood Pressure; Creatine Kinase, MB Form; Cyclooxygenase 2 Inhibitors; Disease Models, Anim	2009
A conditional sequential sampling procedure for drug safety surveillance. Statistics in medicine, 2009, Nov-10, Volume: 28, Issue:25 Topics: Aged; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Evaluation; Drug-Related Si	2009
Bringing the FDA's Information to Market. Archives of internal medicine, 2009, Nov-23, Volume: 169, Issue:21 Topics: Adverse Drug Reaction Reporting Systems; Advertising; Cyclooxygenase 2 Inhibitors; Drug Industry; Dr	2009
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C	2009
Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study. European journal of clinical pharmacology, 2010, Volume: 66, Issue:6 Topics: Angina, Unstable; Celecoxib; Cerebral Infarction; Cyclooxygenase 2 Inhibitors; Databases, Factual; D	2010
Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. Journal of molecular and cellular cardiology, 2010, Volume: 49, Issue:1 Topics: Animals; Cardiomegaly; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Heart Failure; Heart Ventricle	2010
International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction. Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:8 Topics: Acute Disease; Aged; Aged, 80 and over; Cyclooxygenase 2 Inhibitors; Female; Gastrointestinal Hemorr	2010
Exogenous estrogen does not attenuate the association between rofecoxib and myocardial infarction in perimenopausal women. Journal of cardiovascular pharmacology, 2011, Volume: 57, Issue:2 Topics: Aged; Cardiotonic Agents; Cohort Studies; Estrogen Replacement Therapy; Estrogens; Female; Humans; L	2011
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. European heart journal, 2012, Volume: 33, Issue:15 Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic	2012
A positive event dependence model for self-controlled case series with applications in postmarketing surveillance. Biometrics, 2013, Volume: 69, Issue:1 Topics: Computer Simulation; Esomeprazole; Humans; Lactones; Models, Statistical; Myocardial Infarction; Ome	2013
Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study. PloS one, 2013, Volume: 8, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Denmark; Diclofenac; Female; Follow-Up Studies; Hospi	2013
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Jun-25, Volume: 166, Issue:13 Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardi	2002
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Archives of internal medicine, 2003, Feb-24, Volume: 163, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase Inhib	2003
Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. American journal of physiology. Heart and circulatory physiology, 2004, Volume: 286, Issue:4 Topics: Animals; Cardiomegaly; Collagen; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhib	2004
Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. The American journal of medicine, 2004, May-01, Volume: 116, Issue:9 Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Decision Support Techniques; Female; Gastroi	2004
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation, 2004, May-04, Volume: 109, Issue:17 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C	2004
Rofecoxib use increases acute myocardial infarction risk. Circulation, 2004, May-04, Volume: 109, Issue:17 Topics: Aortic Aneurysm, Abdominal; Benzazepines; Cardiology; Cholesterol; Female; Heart Failure; Humans; La	2004
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation, 2004, Jun-22, Volume: 109, Issue:24 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Case-	2004
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. Bulletin du cancer, 2004, Volume: 91 Spec No Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C	2004
Failing the public health--rofecoxib, Merck, and the FDA. The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17 Topics: Adverse Drug Reaction Reporting Systems; Advertising; Arthritis, Rheumatoid; Clinical Trials as Topi	2004
Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science (New York, N.Y.), 2004, Oct-15, Volume: 306, Issue:5695 Topics: Blood Pressure; Clinical Trials as Topic; Colonic Polyps; Cyclooxygenase Inhibitors; Drug and Narcot	2004
US government agency to investigate FDA over rofecoxib. BMJ (Clinical research ed.), 2004, Oct-23, Volume: 329, Issue:7472 Topics: Drug Approval; Humans; Interprofessional Relations; Lactones; Myocardial Infarction; Stroke; Sulfone	2004
Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2004, Oct-26, Volume: 171, Issue:9 Topics: Drug and Narcotic Control; Drug Industry; Humans; Lactones; Myocardial Infarction; Randomized Contro	2004
[Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?]. MMW Fortschritte der Medizin, 2004, Oct-14, Volume: 146, Issue:42 Topics: Colonic Polyps; Cyclooxygenase Inhibitors; Germany; Humans; Lactones; Long-Term Care; Myocardial Inf	2004
Rofecoxib and dental prescribing. British dental journal, 2004, Nov-13, Volume: 197, Issue:9 Topics: Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Pharmacopoeias as Topic; Stroke;	2004
MI risk prompts rofecoxib withdrawal. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Nov-01, Volume: 61, Issue:21 Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug and Narcotic Control;	2004
Lessons learned after the withdrawal of rofecoxib. Managed care interface, 2004, Volume: 17, Issue:11 Topics: Clinical Trials as Topic; Cyclooxygenase Inhibitors; Decision Making, Organizational; Humans; Lacton	2004
UK patients seek compensation after taking rofecoxib. BMJ (Clinical research ed.), 2004, Dec-04, Volume: 329, Issue:7478 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Compensation and Redress; Humans; La	2004
Arthritis drug raises risk of sudden heart attack. Health news (Waltham, Mass.), 2004, Volume: 10, Issue:10 Topics: Cyclooxygenase 2; Humans; Isoenzymes; Lactones; Membrane Proteins; Myocardial Infarction; Osteoarthr	2004
Vioxx removed from market. Mayo Clinic women's healthsource, 2004, Volume: 8, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Lactones; Myocardial Infarction; Stroke; Sulfones	2004
Despite warnings, drug giant took long path to Vioxx recall. The New York times on the Web, 2004, Nov-14 Topics: Drug Approval; Drug Industry; Humans; Lactones; Liability, Legal; Myocardial Infarction; Product Sur	2004
COX-2 inhibitor use after Vioxx: careful balance or end of the rope? The American journal of managed care, 2004, Volume: 10, Issue:11 Pt 1 Topics: Contraindications; Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Myocardial Infarction	2004
[Rofecoxib (Vioxx) has been withdrawn, what next?]. Duodecim; laaketieteellinen aikakauskirja, 2004, Volume: 120, Issue:21 Topics: Dose-Response Relationship, Drug; Drug and Narcotic Control; Finland; Forecasting; Humans; Lactones;	2004
The sad story of Vioxx, and what we should learn from it. Cleveland Clinic journal of medicine, 2004, Volume: 71, Issue:12 Topics: Arthritis, Rheumatoid; Drug Approval; Drug Industry; Humans; Lactones; Myocardial Infarction; Produc	2004
Summaries for patients. Cyclooxygenase-2 inhibitors and heart attacks: varying effects? Annals of internal medicine, 2005, Feb-01, Volume: 142, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase Inhib	2005
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Annals of internal medicine, 2005, Feb-01, Volume: 142, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confo	2005
How to avoid another 'Vioxx'. Nature reviews. Drug discovery, 2005, Volume: 4, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Infarction; Clinical Trials as Topic; Cyclooxygena	2005
FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ (Clinical research ed.), 2005, Feb-26, Volume: 330, Issue:7489 Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Membrane	2005
Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib). European journal of epidemiology, 2005, Volume: 20, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug and	2005
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. Journal of the National Cancer Institute, 2005, Apr-20, Volume: 97, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Ce	2005
The Vioxx fallout. Minnesota medicine, 2005, Volume: 88, Issue:3 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumat	2005
Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Archives of internal medicine, 2005, May-09, Volume: 165, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celec	2005
Evidence in Vioxx suits shows intervention by Merck officials. The New York times on the Web, 2005, Apr-24 Topics: Clinical Trials as Topic; Death; Deception; Drug Industry; Drugs, Investigational; Humans; Lactones;	2005
Merck VIOXX "warning" is questioned. Texas medicine, 2005, Volume: 101, Issue:5 Topics: Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Industry; Drug Labeling; Humans; Lactones;	2005
The lessons of Vioxx--drug safety and sales. The New England journal of medicine, 2005, Jun-23, Volume: 352, Issue:25 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase Inhibitors; Drug Evaluation; Drug	2005
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. Yale journal of health policy, law, and ethics, 2005,Summer, Volume: 5, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromans; Clinical Trials as Topic; Cyclooxygena	2005
Concerns about COX-2 painkillers. They're easier on the stomach, potentially harder on your heart. Heart advisor, 2002, Volume: 5, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myo	2002
The Vioxx debacle revisited. The American journal of medicine, 2005, Volume: 118, Issue:9 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Pyrazoles; Sulfonamid	2005
Merck cleared in personal injury case against Vioxx. BMJ (Clinical research ed.), 2005, Nov-12, Volume: 331, Issue:7525 Topics: Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Liability, Legal; Male; Middle Aged; Myo	2005
[Rofecoxib increases myocardial infarction risk in seniors]. Medizinische Monatsschrift fur Pharmazeuten, 2005, Volume: 28, Issue:11 Topics: Aged; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Myocardial Infarction; Sulfones	2005
Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making. Journal of clinical pharmacology, 2006, Volume: 46, Issue:1 Topics: Adverse Drug Reaction Reporting Systems; Bias; Case-Control Studies; Cohort Studies; Confounding Fac	2006
Manipulating a journal article. The New York times on the Web, 2005, Dec-11 Topics: Clinical Trials as Topic; Deception; Drug Industry; Editorial Policies; Humans; Lactones; Myocardial	2005
NEJM editor gives pretrial evidence in Vioxx case. BMJ (Clinical research ed.), 2006, Feb-04, Volume: 332, Issue:7536 Topics: Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Myocardial Infarction; Periodicals as To	2006
The vexations of Vioxx. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006, Feb-14, Volume: 174, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Approval; Drug Industry; Humans; Lactones; Liability,	2006
Expression of concern reaffirmed. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Lactones; Myocard	2006
Response to expression of concern regarding VIGOR study. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Data Interpretation, Statistical; Gastrointestinal D	2006
Observational studies and the withdrawal of rofecoxib. Pharmacoepidemiology and drug safety, 2006, Volume: 15, Issue:3 Topics: Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Drug Labeli	2006
NEJM stands by its criticism of Vioxx study. BMJ (Clinical research ed.), 2006, Mar-04, Volume: 332, Issue:7540 Topics: Cyclooxygenase 2 Inhibitors; Humans; Lactones; Myocardial Infarction; Periodicals as Topic; Research	2006
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug safety, 2006, Volume: 29, Issue:3 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib;	2006
Response to expression of concern regarding VIGOR study. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Arthritis, Rheumatoid; Data Interpretation, Statistical; Gastrointestinal Diseases; Humans; Lactones	2006
Court awards claimant 13.5m dollars in rofecoxib lawsuit. BMJ (Clinical research ed.), 2006, Apr-22, Volume: 332, Issue:7547 Topics: Aged; Cyclooxygenase 2 Inhibitors; Drug Industry; Humans; Lactones; Liability, Legal; Male; Myocardi	2006
[Assessment of the number of cardio- and cerebrovascular events due to rofecoxib (Vioxx) in Germany between 2001 and 2004]. Medizinische Klinik (Munich, Germany : 1983), 2006, Mar-15, Volume: 101, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Cause of Death; Cerebral Infarction; Clinical Trials as Topic; Cross	2006
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006, May-23, Volume: 174, Issue:11 Topics: Age Factors; Aged; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Drug Administration Sched	2006
Dispute over Vioxx study plays out in New England journal. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006, May-09, Volume: 174, Issue:10 Topics: Canada; Drug Industry; Ethics, Research; Humans; Lactones; Myocardial Infarction; New England; Perio	2006
Evaluating drug effects in the post-Vioxx world: there must be a better way. Circulation, 2006, May-09, Volume: 113, Issue:18 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug	2006
Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs. Circulation, 2006, May-09, Volume: 113, Issue:18 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug	2006
Celecoxib shown effective in preventing colon polyps. Journal of the National Cancer Institute, 2006, May-17, Volume: 98, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib	2006
Balancing the cyclooxygenase portfolio. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006, May-23, Volume: 174, Issue:11 Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Dr	2006
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation, 2006, Jun-27, Volume: 113, Issue:25 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Confidence Intervals; C	2006
Merck's actions surrounding Vioxx. PLoS medicine, 2006, Volume: 3, Issue:6 Topics: Advertising; Bioethical Issues; Cyclooxygenase 2 Inhibitors; Drug Industry; Humans; Lactones; Myocar	2006
NEJM "failed its readers" by delay in publishing its concerns about VIGOR trial. BMJ (Clinical research ed.), 2006, Jul-15, Volume: 333, Issue:7559 Topics: Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Myocardial Infarction; Peri	2006
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart (British Cardiac Society), 2007, Volume: 93, Issue:2 Topics: Aged; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2 Inhibito	2007
Lapses at the new England journal of medicine. Journal of the Royal Society of Medicine, 2006, Volume: 99, Issue:8 Topics: Boston; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug Industry; Gastrointestinal Disea	2006
The COX-2 controversy continues ...but NSAIDs are still in the lead. New studies shed light on risks associated with popular arthritis painkillers. Health news (Waltham, Mass.), 2006, Volume: 12, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Myocardial I	2006
US judge dismisses 50m dollars damages in Vioxx lawsuit. BMJ (Clinical research ed.), 2006, Sep-09, Volume: 333, Issue:7567 Topics: Cyclooxygenase 2 Inhibitors; Drug Industry; Humans; Lactones; Liability, Legal; Louisiana; Myocardia	2006
[Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Cardiovascular Diseases; Cerebrovascular Disorders; Confidence Intervals; Controlled Clinical Trials	2006
[How many harmed by rofecoxib in Germany?]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Confidence Intervals; Controlled Clin	2006
[Overestimated]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topi	2006
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis and rheumatism, 2006, Volume: 54, Issue:11 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; F	2006
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Stu	2007
Quebec allows Vioxx class-action suit. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Jan-02, Volume: 176, Issue:1 Topics: Cyclooxygenase 2 Inhibitors; Drug Industry; Humans; Lactones; Myocardial Infarction; Quebec; Sulfone	2007
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Circulation, 2007, Jan-23, Volume: 115, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib	2007
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 I	2007
A proposed fairer method for conducting rofecoxib trials. Medical hypotheses, 2007, Volume: 69, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy	2007
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice? Southern medical journal, 2007, Volume: 100, Issue:8 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl	2007
The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PloS one, 2007, Sep-05, Volume: 2, Issue:9 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Population Surveillan	2007
Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:12 Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Celecoxib; Competitive Medical Plans; Health Ma	2007
Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance? Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:5 Topics: Adult; Aged; Causality; Celecoxib; Computer Simulation; Cyclooxygenase 2 Inhibitors; Databases, Fact	2008
94% of patients suing Merck over rofecoxib agree to company's offer. BMJ (Clinical research ed.), 2008, Mar-15, Volume: 336, Issue:7644 Topics: Cyclooxygenase 2 Inhibitors; Drug Industry; Humans; Lactones; Liability, Legal; Myocardial Infarctio	2008
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:6 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coh	2008
More on subgroup analyses in clinical trials. The New England journal of medicine, 2008, May-08, Volume: 358, Issue:19 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Lactone	2008
[New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)]. MMW Fortschritte der Medizin, 2001, Sep-06, Volume: 143, Issue:35-36 Topics: Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase I	2001
Is concern about cardiovascular events with the new coxib class of drugs justified? Medscape women's health, 2001, Volume: 6, Issue:5 Topics: Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Drug Evaluation; Humans; Lac	2001
COX-2 inhibition and thrombotic tendency. The Medical journal of Australia, 2002, Jan-21, Volume: 176, Issue:2 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Pyrazoles; Sulfonamid	2002
Biomedicine. Back to an aspirin a day? Science (New York, N.Y.), 2002, Apr-19, Volume: 296, Issue:5567 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carotid Artery Injuries; Cell Division; Clinical T	2002
Why do COX-2 inhibitors increase risk of cardiovascular events? Lancet (London, England), 2002, Apr-20, Volume: 359, Issue:9315 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc	2002

rofecoxib and Cardiovascular Stroke

Research Excerpts

Research

Studies (119)

Authors

Clinical Trials (3)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Roy, S	1
Ye, T	1
Ertefaie, A	1
Vo, TT	1
Flory, J	1
Hennessy, S	2
Small, D	1
Moore, N	1
Brenner, GB	1
Makkos, A	1
Nagy, CT	1
Onódi, Z	1
Sayour, NV	1
Gergely, TG	1
Kiss, B	1
Görbe, A	1
Sághy, É	1
Zádori, ZS	1
Lázár, B	1
Baranyai, T	1
Varga, RS	1
Husti, Z	1
Varró, A	1
Tóthfalusi, L	1
Schulz, R	1
Baczkó, I	1
Giricz, Z	1
Ferdinandy, P	1
Jordan, F	1
Quinn, TJ	1
McGuinness, B	1
Passmore, P	1
Kelly, JP	1
Tudur Smith, C	1
Murphy, K	1
Devane, D	1
Masclee, GMC	1
Straatman, H	1
Arfè, A	1
Castellsague, J	2
Garbe, E	2
Herings, R	1
Kollhorst, B	1
Lucchi, S	1
Perez-Gutthann, S	1
Romio, S	1
Schade, R	1
Schink, T	1
Schuemie, MJ	1
Scotti, L	1
Varas-Lorenzo, C	4
Valkhoff, VE	1
Villa, M	1
Sturkenboom, MCJM	1
A Wahab, I	1
Pratt, NL	1
Kalisch, LM	1
Roughead, EE	1
Nadareishvili, Z	1
Michaud, K	1
Hallenbeck, JM	1
Wolfe, F	1
van der Hoorn, JW	1
Jukema, JW	1
Bekkers, ME	1
Princen, HM	1
Corda, S	1
Emeis, JJ	1
Steendijk, P	1
Curtis, JR	1
Cheng, H	1
Delzell, E	1
Fram, D	1
Kilgore, M	1
Saag, K	1
Yun, H	1
Dumouchel, W	1
Flier, S	1
Buhre, W	1
Warner, JJ	1
Weideman, RA	1
Kelly, KC	1
Brilakis, ES	1
Banerjee, S	1
Cunningham, F	1
Harford, WV	1
Kazi, S	1
Little, BB	1
Cryer, B	1
Tan, S	1
Tambar, S	1
Chohan, S	1
Ramsey-Goldman, R	1
Lee, C	1
Carnieto, A	1
Dourado, PM	1
Luz, PL	1
Chagas, AC	1
Li, L	1
Ross, JS	1
Madigan, D	1
Hill, KP	1
Egilman, DS	1
Wang, Y	2
Krumholz, HM	1
Woloshin, S	1
Schwartz, LM	1
Ray, WA	1
Chung, CP	1
Murray, KT	1
Stein, CM	1
Daugherty, JR	1
Arbogast, PG	1
García-Rodríguez, LA	1
Gudbjornsson, B	1
Thorsteinsson, SB	1
Sigvaldason, H	1
Einarsdottir, R	1
Johannsson, M	1
Zoega, H	1
Halldorsson, M	1
Thorgeirsson, G	1
Streicher, JM	1
Kamei, K	1
Ishikawa, TO	1
Herschman, H	1
Metcalfe, C	1
Wheeler, BW	1
Gunnell, D	1
Martin, RM	1
Wade, KC	1
Ellenberg, JH	1
Grosser, T	1
Brensinger, CM	1
Kimmel, SE	2
Bäck, M	1
Yin, L	1
Ingelsson, E	1
Simpson, SE	1
Olsen, AM	1
Fosbøl, EL	1
Lindhardsen, J	1
Andersson, C	1
Folke, F	1
Nielsen, MB	1
Køber, L	2
Hansen, PR	1
Torp-Pedersen, C	2
Gislason, GH	2
Wooltorton, E	1
Howes, LG	1
Krum, H	1
Mamdani, M	1
Rochon, P	1
Juurlink, DN	1
Anderson, GM	1
Kopp, A	1
Naglie, G	1
Austin, PC	1
Laupacis, A	1
LaPointe, MC	1
Mendez, M	1
Leung, A	1
Tao, Z	1
Yang, XP	1
Choi, HK	1
Seeger, JD	1
Kuntz, KM	1
Solomon, DH	2
Schneeweiss, S	2
Glynn, RJ	1
Kiyota, Y	1
Levin, R	1
Mogun, H	1
Avorn, J	2
SoRelle, R	1
Monakier, D	1
Mates, M	1
Klutstein, MW	1
Balkin, JA	1
Rudensky, B	1
Meerkin, D	1
Tzivoni, D	1
García Rodríguez, LA	2
Maguire, A	1
González-Pérez, A	1
Lamarque, D	1
Topol, EJ	2
Couzin, J	1
Lenzer, J	2
Sibbald, B	3
Brune, K	1
Zacher, J	1
Pemberton, MN	1
Thompson, CA	1
Giaquinta, D	1
Dyer, C	1
Berenson, A	2
Harris, G	1
Meier, B	1
Pollack, A	1
Fendrick, AM	1
Idänpään-Heikkilä, JE	1
Klaukka, T	1
Karha, J	1
Berlin, JA	1
Reilly, M	1
Jaskowiak, J	1
Kishel, L	1
Chittams, J	1
Strom, BL	1
Frantz, S	1
Carné, X	1
Cruz, N	1
Vanchieri, C	1
Palmer, K	1
Johnsen, SP	1
Larsson, H	1
Tarone, RE	1
McLaughlin, JK	1
Nørgård, B	1
Friis, S	1
Sørensen, HT	1
Allen, TS	1
Henderson, JH	1
Waxman, HA	1
Epstein, RA	1
Abeles, M	1
Abeles, AM	1
Klasser, GD	1
Epstein, J	1
Hawkey, CJ	3
Fortun, PJ	1
Mayor, S	1
Wasielewski, S	1
Lekakis, JP	1
Vamvakou, G	1
Andreadou, I	1
Ganiatsos, G	1
Karatzis, E	1
Protogerou, A	1
Papaioannou, T	1
Ikonomidis, I	1
Papamichael, C	1
Mavrikakis, ME	1
Etminan, M	1
Gill, S	1
Fitzgerald, M	1
Samii, A	1
Tanne, JH	3
Curfman, GD	1
Morrissey, S	1
Drazen, JM	1
Bombardier, C	1
Laine, L	1
Burgos-Vargas, R	1
Davis, B	1
Day, R	1
Ferraz, MB	1
Hochberg, MC	1
Kvien, TK	1
Schnitzer, TJ	2
Weaver, A	1
Watson, DJ	2
Santanello, NC	1
Huang, WF	1
Hsiao, FY	1
Tsai, YW	1
Wen, YW	1
Shih, YT	1
Reicin, A	1
Shapiro, D	1
Hernández-Díaz, S	1
Sawicki, PT	1
Bender, R	1
Selke, GW	1
Klauber, J	1
Gutschmidt, S	1
Lévesque, LE	2
Brophy, JM	2
Zhang, B	2
Kondro, W	1
Roth-Cline, MD	1
Nelson, NJ	1
Armstrong, PW	1
Jacobsen, S	1
Rasmussen, JN	1
Rasmussen, S	1
Buch, P	1
Friberg, J	1
Schramm, TK	1
Abildstrom, SZ	1
Madsen, M	1
Heinley, M	1
Dobson, R	1
Smith, R	1
Charatan, F	2
Lee, YH	1
Ji, JD	1
Song, GG	1
Mühlbauer, B	1
Timm, J	1
Scharnetzky, E	1
Andersohn, F	1
Schill, W	1
Pigeot, I	1
Höer, A	1
Häussler, B	1
Wang, PS	1
Rassen, J	1
Brookhart, MA	1
Rahme, E	2
Kong, SX	1
Toubouti, Y	1
LeLorier, J	1
Jugdutt, BI	1
Nedjar, H	1
Chen, LC	1
Ashcroft, DM	1
Hellstrom, HR	1
Singh, H	1
Brownstein, JS	1
Sordo, M	1
Kohane, IS	1
Mandl, KD	1
Brown, JS	1
Kulldorff, M	1
Chan, KA	1
Davis, RL	1
Graham, D	1
Pettus, PT	1
Andrade, SE	1
Raebel, MA	1
Herrinton, L	1
Roblin, D	1
Boudreau, D	1
Smith, D	1
Gurwitz, JH	1
Gunter, MJ	1
Platt, R	1
van Staa, TP	1
Smeeth, L	1
Persson, I	1
Parkinson, J	1
Leufkens, HG	1
Cunnington, M	1
Webb, D	1
Qizilbash, N	1
Blum, D	1
Mander, A	1
Funk, MJ	1
Weil, J	1
Pocock, SJ	1
Lubsen, J	1
Zeidler, H	1
Fenn, CG	1
Vane, JR	1
Frankish, H	1